A5018669695- Macrophage Migration Inhibitory Factor
- Chronic Lymphocytic Leukemia Research
- Nuclear Receptors and Signaling
- Lymphoma Diagnosis and Treatment
- Eosinophilic Esophagitis
- Palliative Care and End-of-Life Issues
- Inflammatory Bowel Disease
- Galectins and Cancer Biology
- Microscopic Colitis
- Viral-associated cancers and disorders
- Patient Dignity and Privacy
- HIV/AIDS drug development and treatment
- Diet and metabolism studies
- Single-cell and spatial transcriptomics
- Immune cells in cancer
- Phagocytosis and Immune Regulation
- Diet, Metabolism, and Disease
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Liver Disease Diagnosis and Treatment
University Hospital of Zurich
2020-2024
University of Zurich
2020-2023
RWTH Aachen University
2017-2022
Ludwig-Maximilians-Universität München
2017-2022
Universitätsklinikum Aachen
2017
MIF is a chemokine-like cytokine that plays role in the pathogenesis of inflammatory and cardiovascular disorders. It binds to chemokine-receptors CXCR2/CXCR4 trigger atherogenic leukocyte migration albeit lacking canonical chemokine structures. We recently characterized an N-like-loop Pro-2-residue as critical molecular determinants CXCR4/MIF binding-site identified allosteric agonism mechanism distinguishes CXCR4-binding from cognate ligand CXCL12. By using peptide spot-array technology,...
Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine ex vivo (pharmacoscopy) with bulk DNA, RNA, protein analyses, alongside clinical data from 21 rrAML patients. Unsupervised integration reveals reduced response the Bcl-2 inhibitor venetoclax (VEN) patients treated both hypomethylating agent (HMA) VEN, compared those pre-exposed chemotherapy HMA alone....
Background and study aims: Acute health service requires focused palliative care (PC). This was performed to provide guidance for the establishment of a consultation (PCCS). Patients methods: conceived as retrospective single-center observing, analyzing evaluating initial setup PCCS from 1 May 2015 31 2018. Muenster University Hospital with advanced life-limiting diseases, identified require PC, were included. Results: requested various departments, between 20 80 patients per month,...
The genomic landscape of mantle cell lymphoma (MCL) includes frequent alterations TP53 , ATM CCND1 and KMT2D . Thus far, the mutational provides little information for treatment stratification. We characterized a cohort MCL by targeted next generation sequencing discovered SAMHD1 as novel recurrently mutated gene (8.5% investigated cases, 4/47 samples). Furthermore, we provide evidence in vitro resistance patient-derived cells to cytarabine fludarabine.